Generation Bio Co. (NASDAQ:GBIO) Shares Bought by Barclays PLC

Barclays PLC lifted its position in shares of Generation Bio Co. (NASDAQ:GBIO) by 165.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 76,430 shares of the company’s stock after buying an additional 47,639 shares during the period. Barclays PLC’s holdings in Generation Bio were worth $189,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in GBIO. SG Americas Securities LLC acquired a new position in Generation Bio during the third quarter valued at approximately $42,000. Cubist Systematic Strategies LLC raised its stake in shares of Generation Bio by 91.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock valued at $54,000 after acquiring an additional 9,075 shares during the period. American Century Companies Inc. lifted its holdings in shares of Generation Bio by 199.3% during the 2nd quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock valued at $90,000 after acquiring an additional 21,167 shares in the last quarter. Rhumbline Advisers boosted its position in Generation Bio by 7.4% during the 2nd quarter. Rhumbline Advisers now owns 78,903 shares of the company’s stock worth $222,000 after purchasing an additional 5,430 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Generation Bio by 8.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 164,573 shares of the company’s stock valued at $464,000 after purchasing an additional 13,104 shares in the last quarter. 95.22% of the stock is owned by hedge funds and other institutional investors.

Generation Bio Price Performance

Generation Bio stock opened at $1.14 on Tuesday. Generation Bio Co. has a 12-month low of $0.75 and a 12-month high of $4.65. The company has a market capitalization of $76.14 million, a price-to-earnings ratio of -0.52 and a beta of 2.72. The firm’s fifty day moving average price is $1.49 and its 200 day moving average price is $2.20.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on GBIO. Wedbush restated an “outperform” rating and set a $5.00 price objective on shares of Generation Bio in a research note on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $10.00 price target on shares of Generation Bio in a research report on Wednesday, October 23rd.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.